Peroxisome Proliferator-Activated Receptor Agonists: Do They Increase Cardiovascular Risk?
Table 2
The effect of TZDs on CV risk. The table shows a comparison between rosiglitazone and pioglitazone on lipid profile and HbA1c levels in various studies [19–23].